Lipid-Polyglutamate Nanoparticle Vaccine Platform
Por:
D. VAN LYSEBETTEN, A. MALFANTI, K. DESWARTE, K. KOYNOV, B. GOLBA, T. YE, Z. ZHONG, S. KASMI, A. LAMOOT, Y. CHEN, S. VAN HERCK, B. LAMBRECHT, N. SANDERS, S. LIENENKLAUS, S. DAVID, M. VICENT, S. DE KOKER and B. DE GEEST
Publicada:
10 feb 2021
Ahead of Print:
1 ene 2021
Resumen:
Peptide-based subunit vaccines are attractive in view of personalized cancer vaccination with neo-antigens, as well as for the design of the newest generation of vaccines against infectious diseases. Key to mounting robust antigen-specific immunity is delivery of antigen to antigen-presenting (innate immune) cells in lymphoid tissue with concomitant innate immune activation to promote antigen presentation to T cells and to shape the amplitude and nature of the immune response. Nanoparticles that co-deliver both peptide antigen and molecular adjuvants are well suited for this task. However, in the context of peptide-based antigen, an unmet need exists for a generic strategy that allows for co-encapsulation of peptide and molecular adjuvants due to the stark variation in physicochemical properties based on the amino acid sequence of the peptide. These properties also strongly differ from those of many molecular adjuvants. Here, we devise a lipid nanoparticle (LNP) platform that addresses these issues. Key in our concept is poly(L-glutamic acid) (PGA), which serves as a hydrophilic backbone for conjugation of, respectively, peptide antigen (Ag) and an imidazoquinoline (IMDQ) TLR7/8 agonist as a molecular adjuvant. Making use of the PGA's polyanionic nature, we condensate PGA-Ag and PGA-IMDQ into LNP by electrostatic interaction with an ionizable lipid. We show in vitro and in vivo in mouse models that LNP encapsulation favors uptake by innate immune cells in lymphoid tissue and promotes the induction of Ag-specific T cells responses both after subcutaneous and intravenous administration.
Filiaciones:
D. VAN LYSEBETTEN:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
:
Ctr Invest Principe Felipe CIPF, Polymer Therapeut Lab, Valencia 46012, Spain
K. DESWARTE:
Univ Ghent, VIB Ctr Inflammat Res, Dept Internal Med & Pediat, B-9052 Ghent, Belgium
K. KOYNOV:
Max Planck Inst Polymer Res, D-55128 Mainz, Germany
B. GOLBA:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
T. YE:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
Z. ZHONG:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
S. KASMI:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
A. LAMOOT:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
Y. CHEN:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
S. VAN HERCK:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
B. LAMBRECHT:
Univ Ghent, VIB Ctr Inflammat Res, Dept Internal Med & Pediat, B-9052 Ghent, Belgium
N. SANDERS:
Univ Ghent, Lab Gene Therapy, B-9820 Merelbeke, Belgium
S. LIENENKLAUS:
Hannover Med Sch, Inst Lab Anim Sci, D-30625 Hannover, Germany
Hannover Med Sch, Inst Immunol, D-30625 Hannover, Germany
S. DAVID:
Virovax, Lawrence, KS 66047 USA
:
Ctr Invest Principe Felipe CIPF, Polymer Therapeut Lab, Valencia 46012, Spain
S. DE KOKER:
Etherna Immunotherapies Nv, B-2845 Niel, Belgium
B. DE GEEST:
Univ Ghent, Dept Pharmaceut, B-9000 Ghent, Belgium
Green Accepted
|